Key clinical point: The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel is not cost effective when used as first-line treatment for metastatic non–small cell lung cancer.
Major finding: The incremental cost‐effectiveness ratio for atezolizumab, bevacizumab, carboplatin, and paclitaxel was $568,967 per quality-adjusted life-years, compared with bevacizumab, carboplatin, and paclitaxel, and $516,114 per quality-adjusted life-year, compared with carboplatin and paclitaxel.
Study details: A Markov modeling study comparing lifetime cost and effectiveness of first-line combination regimens for non–small cell lung cancer.
Disclosures: Dr. Wan did not report any relevant conflicts of interest. The study was supported by grants from the National Natural Science Foundation of China and the research project of the Health and Family Planning Commission of Hunan province.
Wan X et al. Cancer. 2019 Jul 9. doi: 10.1002/cncr.32368